How do hormones affect tumor DNA in men with breast cancer?

February 14, 2018, The Netherlands Cancer Institute

Breast cancer in men is rare, and men with breast cancer receive the same anti-hormonal therapy as women. Often with effect, but there was no scientific basis for it before now. Cancer researchers led by Wilbert Zwart from the Netherlands Cancer Institute and Oncode Institute are now the first to clarify how hormones affect tumor DNA in men with breast cancer.

Most tumors in men barely differ biologically from those in women. But in tumors that react badly to anti-hormonal , the researchers saw subtle differences between the two sexes. These new insights constitute another major step towards the best personalized treatment for men and women.

The researchers published their findings on February 2 in the scientific journal Nature Communications.

Therapy based on treatment of women

Approximately 100 men per year are diagnosed with breast cancer in the Netherlands, compared to more than 14,000 women. In the vast majority of breast cancers, both in men and women, the tumor is hormone-sensitive. This means that hormones, like estrogen, influence the DNA, causing the tumor to grow and eventually to spread. Anti-hormonal therapy, aimed at blocking the , is therefore also often part of the treatment for men. Often with effect but also with stressful side effects. However, there was not yet a scientific basis for giving men the same treatment as women. The researchers, led by Wilbert Zwart, have now mapped the hormonal function over the entire tumor DNA for the first time and compared men and women.

The first conclusion was that by far most of the breast tumors in men and women are barely distinguishable from each other. This provides a scientific basis for the current practice of giving men and women the same anti-hormonal therapy.

But as with women with hormone-sensitive , there are also men whose still comes back despite the treatment. This group is therefore likely to benefit from a different or supplementary approach. And it is precisely in this group of men that the DNA profiles of the tumor appear to be gender-specific.

Wilbert Zwart: "We had already seen that very specific patterns in women are predictive of the course of the disease. In patients with a less favorable course of the disease, other sites of the DNA are active under the influence of hormones. That says something about the therapy sensitivity of each individual and this knowledge is essential when looking for a personalized therapy. In men, we also see specific patterns that are different than in . If we are to work towards a personalized for men, the selection of medicines may, therefore, have to be slightly different. But a lot of research is still needed for this."

Explore further: Breast cancer treatment link to chronic disease

More information: Tesa M. Severson et al. Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer, Nature Communications (2018). DOI: 10.1038/s41467-018-02856-2

Related Stories

Breast cancer treatment link to chronic disease

January 16, 2018
Women who have undergone hormonal therapy for breast cancer are at increased risk of developing chronic conditions later in life, according to new research.

Pregnancy not dangerous for women who had breast cancer

June 4, 2017
Becoming pregnant after a diagnosis of breast cancer does not raise the risk of the cancer returning, said the largest study of its kind to date, released Saturday at a major cancer conference.

Soybean consumption may be beneficial for some women with breast cancer

June 21, 2017
It can be confusing to know what to eat to lower your risk of breast cancer. Research is mixed, for example, on whether women should avoid soy foods, such as tofu and soybeans, or try to eat more of them. The question is ...

Estrogen plus progestin use linked with increased breast cancer incidence and mortality

March 29, 2013
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be ...

Stopping hormones might help breast cancer to regress

February 28, 2012
As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, ...

Pregnancy after breast cancer does not increase chance of recurrence

June 5, 2017
Findings from a retrospective study of 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including ...

Recommended for you

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.